Profile data is unavailable for this security.
About the company
Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
- Revenue in DKK (TTM)33.83m
- Net income in DKK-50.02m
- Incorporated1917
- Employees33.00
- LocationBioporto A/STuborg Havnevej 15, St.HELLERUP 2900DenmarkDNK
- Phone+45 45290000
- Fax+45 45290001
- Websitehttps://bioporto.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Omda AS | 266.05m | 57.70m | 426.46m | 295.00 | 7.36 | 11.48 | 4.38 | 1.60 | 4.35 | 4.35 | 20.60 | 2.79 | 0.5886 | 238.36 | 10.38 | 1,434,162.00 | 13.80 | -4.92 | 18.03 | -6.37 | 92.89 | 90.22 | 23.45 | -9.83 | 1.14 | 2.56 | 0.8946 | -- | 12.30 | 19.83 | 179.30 | -- | -3.93 | -- |
OssDsign AB | 81.08m | -74.74m | 447.66m | 27.00 | -- | 3.03 | -- | 5.52 | -1.40 | -1.40 | 1.43 | 2.30 | 0.4311 | 2.50 | 6.80 | 2,572,083.00 | -39.74 | -37.92 | -43.39 | -43.56 | 83.94 | 68.10 | -92.18 | -203.06 | 5.92 | -21.65 | 0.0114 | -- | 96.84 | 53.26 | -31.30 | -- | -56.16 | -- |
Gentian Diagnostics ASA | 93.26m | -1.28m | 448.32m | 58.00 | -- | 4.47 | 96.95 | 4.81 | -0.1369 | -0.1369 | 9.43 | 10.20 | 0.7756 | 1.71 | 6.79 | 2,522,379.00 | -1.07 | -10.76 | -1.21 | -11.86 | 51.06 | 41.46 | -1.37 | -26.99 | 4.83 | -- | 0.047 | -- | 32.98 | 27.63 | 54.92 | -- | -4.92 | -- |
Mentice AB | 184.37m | -6.70m | 476.88m | 134.00 | -- | 4.76 | 43.91 | 2.59 | -0.3998 | -0.3998 | 10.95 | 5.97 | 0.9046 | 3.05 | 3.28 | 2,301,221.00 | -3.29 | -7.69 | -6.32 | -13.07 | 85.36 | 83.67 | -3.63 | -10.00 | 1.00 | -- | 0.0382 | -- | 25.54 | 11.74 | 90.81 | -- | -10.83 | -- |
Paxman AB (publ) | 156.86m | 18.81m | 711.70m | 102.00 | 37.92 | 7.43 | 23.09 | 4.54 | 1.50 | 1.50 | 12.54 | 7.67 | 1.31 | 2.74 | 6.56 | 2,624,791.00 | 15.66 | -5.08 | 20.74 | -7.76 | 70.27 | 69.38 | 11.99 | -5.07 | 1.98 | 12.73 | 0.0838 | -- | 43.99 | 29.35 | 180.69 | -- | 6.26 | -- |
Optomed Oyj | 109.71m | -36.19m | 774.49m | 110.00 | -- | 3.79 | -- | 7.06 | -0.2761 | -0.2761 | 0.8501 | 1.40 | 0.4762 | 1.69 | 4.10 | 129,035.10 | -15.71 | -12.95 | -19.11 | -15.90 | 67.77 | 65.69 | -32.98 | -27.84 | 2.67 | -- | 0.1424 | -- | 3.00 | 3.47 | 18.84 | -- | 7.26 | -- |
C Rad AB | 300.92m | 31.67m | 785.48m | 89.00 | 25.44 | 4.22 | 20.80 | 2.61 | 1.43 | 1.43 | 13.57 | 8.61 | 1.20 | 4.90 | 3.05 | 5,266,839.00 | 12.69 | 5.09 | 17.96 | 7.02 | 45.14 | 43.12 | 10.61 | 4.86 | 2.43 | -- | 0.0058 | 0.00 | 40.92 | 17.44 | 375.05 | 10.89 | 33.69 | -- |
BioPorto A/S | 33.83m | -50.02m | 828.40m | 33.00 | -- | 7.90 | -- | 24.49 | -0.1397 | -0.1397 | 0.0941 | 0.244 | 0.2777 | 3.23 | 9.02 | 1,091,290.00 | -41.06 | -71.10 | -51.28 | -96.55 | 71.13 | 63.38 | -147.84 | -239.22 | 5.16 | -- | 0.0517 | -- | 6.87 | 3.54 | 25.81 | -- | -51.56 | -- |
ADDvise Group AB (publ) | 1.01bn | 90.23m | 926.95m | 637.00 | 21.69 | 3.80 | 5.92 | 0.9143 | 0.7191 | 0.7191 | 8.07 | 4.10 | 0.5142 | 7.24 | 5.04 | 2,474,039.00 | 4.58 | 3.72 | 5.63 | 4.77 | 44.82 | 48.95 | 8.91 | 5.89 | 1.36 | 3.24 | 0.6913 | 0.9405 | 44.30 | 38.62 | 27.62 | -- | 30.35 | -- |
Genovis AB | 83.42m | 11.33m | 967.34m | 37.00 | 85.39 | 7.09 | 50.68 | 11.60 | 0.2635 | 0.2635 | 1.94 | 3.17 | 0.4938 | -- | -- | 3,432,973.00 | 6.71 | 18.56 | 7.21 | 21.45 | 64.41 | 65.51 | 13.58 | 23.88 | -- | 697.00 | 0.2718 | 0.00 | 54.54 | 35.56 | 449.56 | -- | 47.59 | -- |
Nordhealth As | 307.63m | -69.51m | 1.08bn | 355.00 | -- | 3.25 | 99.96 | 3.52 | -1.40 | -1.40 | 6.16 | 11.57 | 0.4329 | -- | 6.73 | 1,221,681.00 | -9.78 | -- | -11.11 | -- | 85.82 | -- | -22.59 | -- | -- | -- | 0.00 | -- | 18.60 | -- | 21.96 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Danske Bank A/S (Investment Management)as of 30 Jun 2024 | 650.46k | 0.15% |
Dimensional Fund Advisors Ltd.as of 30 Jun 2024 | 115.24k | 0.03% |
Dimensional Fund Advisors LPas of 05 Sep 2024 | 73.51k | 0.02% |
Sydbank A/S (Investment Management)as of 30 Aug 2024 | 56.47k | 0.01% |